Assay procedure using fluorogenic tracers

Details Assay procedure using fluorogenic tracers Assay procedure using fluorogenic tracers

1997-07-10

2003-06-10

Fredman, Jeffrey (Department: 1655)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091100, C435S091200, C435S091300, C435S091500, C536S023100, C536S024300, C536S024310, C536S024320, C536S024330

Reexamination Certificate

active

06576419

ABSTRACT:

TECHNICAL FIELD
This invention relates generally to biological assays, and more specifically to assay reagents labeled with fluorescent materials which reagents can be “toggled” from an intramolecular dimer to a fluorescent monomer by antibody binding.
STATE OF THE ART
Most clinical assays (e.g., immunoassays, DNA probe assays) are heterogeneous and consist of at least two steps: the binding of an antigen to its antibody, followed by physical separation of the bound from free antigens. In some more sensitive assays (e.g., “ELISA” or “EIA”) multiple steps are required. Homogeneous immunoassays, on the other hand, can distinguish between bound antigens and free ones without the need of additional separation steps. They are simple, rapid, yet more precise, more cost effective, and have the potential for total automation. For these reasons, separation-free assays are preferred in many applications such as biosensors, bioprobes and other automated instrumentation. J. P. Gosling,
Clin. Chem.,
36:1408-1427 (1990), D. W. Chan and M. T. Perlstein, Eds.,
Immunoassay, A Practical Guide
(Academic Press, New York, 1987), and E. F. Ullman and P. L. Khanna,
Methods in Enzymology,
74:28-60 (1981).
However, because of various technical complications homogeneous systems have been difficult to obtain, with the exception of a few assays suitable only for small molecules. J. F. Burd et al.,
Clin. Chem.,
23:1402-1408 (1977), M. E. Jolley et al.,
Clin. Chem.,
27:1190-1197 (1981), and D. L. Morris et al.,
Anal. Chem.,
53:658-665 (1981).
It would be an improvement in the art to develop and characterize new fluorogenic tracer antigens that can be used as “reporter molecules” for the binding event without the need of separation steps and the labeling of antibodies. The development of such tracers could greatly facilitate the automation of a large array of clinical assays, especially of high molecular weight antigens. It would help reduce the operational time and cost, and make such assays more readily accessible to doctors and patients. Also, such tracers would be extremely useful for rapidly screening large numbers of recombinant antibodies generated with genetic engineering techniques, such as those described in C. F. Barbas et al.,
Proc. Natl. Acad. Sci. USA
89:4457-4461 (1992), R. A. Lerner et al.,
Science
258:1313-1314 (1992), and Marks et al.
J. Biol. Chem.
267:16007-16010 (1992).
DISCLOSURE OF THE INVENTION
The invention includes a fluorogenic tracer antigen that obviates the need for separation steps or the labeling of antibodies in the performance of an assay. The tracer is a short antigen-mimicking peptide labeled with both a fluorescent energy transfer donor and fluorescent energy transfer acceptor molecules. When free in solution, the tracer exhibits very low fluorescence due to intramolecular dye dimerization. After binding to an antibody of the native antigen, fluorescence is significantly enhanced as a result of the dissociation of intramolecular dimers brought about by conformational changes in the tracer peptide.
The invention thus includes an immunoassay procedure for detecting and quantifying unknown analyte antibody or analyte antigen in bulk solution, a reagent for use in such an immunoassay procedure, and a process for making such a reagent. The reagent which is used in the present procedure is a peptide epitope that is recognized by the antibody in bulk solution, the peptide epitope conjugated to a pair of fluorescent energy transfer dyes capable of moving between a stacked configuration to exhibit fluorescence quenching and a spaced (unstacked) configuration to exhibit fluorescence.
A procedure for using the previously described reagent in a homogeneous antibody assay includes: placing in bulk solution a conjugate of a peptide epitope for the unknown amount of analyte antibody, and a pair of fluorescent dyes. This reagent is capable of moving between a stacked configuration to exhibit fluorescent quenching and a more spaced configuration to exhibit fluorescence. Also placed into the bulk solution is the unknown antibody which will bind with the peptide epitope which is conjugated to the pair of dyes. When this binding event occurs, the configuration of the pair of dyes will be altered between an initial stacked configuration (when in solution) to an unstacked configuration, when the epitope is bonded to the antibody, with a concomitant increase in fluorescent energy in response to the binding.
It is also within the contemplation of the invention to design a homogenous antigen assay or a homogenous DNA (or RNA) probe assay.
The tracers have uses including homogenous detection of macromolecules (e.g. antibodies, antigens, DNA, and RNA) of clinical interest and rapid screening of recombinant antibodies.


REFERENCES:
patent: 4220450 (1980-09-01), Maggio
patent: 4261968 (1981-04-01), Ullman et al.
patent: 4318981 (1982-03-01), Burd et al.
patent: 4681859 (1987-07-01), Kramer
patent: 4777128 (1988-10-01), Lippa
patent: 4833092 (1989-05-01), Geysen
patent: 4868103 (1989-09-01), Stavrianopoulos et al.
patent: 4975380 (1990-12-01), Hummelen et al.
patent: 4996143 (1991-02-01), Heller et al.
patent: 5037615 (1991-08-01), Kane
patent: 5070025 (1991-12-01), Klein et al.
patent: 5237515 (1993-08-01), Herron et al.
patent: 5326692 (1994-07-01), Brinkley et al.
patent: 5538848 (1996-07-01), Livak et al.
patent: 0 331 126 (1969-09-01), None
patent: 0 070 685 (1983-01-01), None
patent: 0 137 515 (1985-04-01), None
patent: 2 223 096 (1990-03-01), None
patent: WO 87/07385 (1987-12-01), None
patent: WO 92/00388 (1992-01-01), None
Parkhurst et al, “Kinetic studies by fluorescence resonance energy transfer employing a double-labeled oligonucleotide: hybridization to the oligonucleotide complement and to single stranded DNA”, Biochemistry 34:285-292, Jan. 1995.*
Parkhurst et al, “Kinetic studies of oligonucleotide DNA hybridization in solution by fluorescence resonance energy transfer”, Abstracts Biophysical Journal 64(2):A266. Feb. 1993.*
*Aguirresacona et al., “Spectroscopic and Thermodynamic Study on the Aggregation of Rhodamines in Solution”,Journal of Chemical Eduction,vol. 66, No. 10, pp. 866-869, Oct. 1989.
*Arbeloa et al., “Dimeric States of Rhodamine B”,Chemical Physics Letters,vol. 87, No. 6, pp. 556-560, Apr., 1982.
Bailey et al., “On the use of fluorescent labels in immunoassay”,J. Pharm.&Biomed. Anal.,vol. 5, No. 7, pp. 649-658, 1987.
*Barnard et al., “Chemical Sensors Based on Controlled-Release Polymer Systems”,Science,vol. 25, pp. 927-929, Feb. 22, 1991.
*Bates et al., “Comparative Properties of Monoclonal Antibodies Comprising a High-Affinity Anti-Fluorescyl Idiotype Family”,Molecular Immunology,vol. 22, No. 8, pp. 871-877, 1985.
*Bird et al., “Single-Chain Antigen-Binding Proteins”,Science,vol. 242, pp. 423-426, Oct. 21, 1988.
Carlsen et al., “Human Chorionic Gonadotropin Linear Amino Acid Sequence of the &bgr; Subunit”,J. Biol. Chem.,vol. 248, No. 19, pp. 6810-6827, 1973.
*Edmundson et al., “A Search For Site-Filling Ligands in the Mcg Bence-Jones Dimer: Crystal Binding Studies of Fluorescent Compounds”,Molecular Immunology,vol. 21, No. 7, pp. 561-576, 1984.
*Farkas et al., “Fluorescence properties of bichromophoric molecules”,Spectrochimica,vol. 48A, No. 1, pp. 95-99, 1992.
Gosling, James P., “A Decade of Development in Immunoassay Methodology”,Clinical Chemistry,vol. 36, No. 8, pp. 1408-1427, 1990.
*Haas et al., “Distribution of End-to-End Distances of Oligopeptides in Solution as Estimated by Energy Transfer”,Proc. Natl. Acad. Sci USA,vol. 72, No. 5, pp. 1807-1811, May 1975.
*Herman et al., “Dynamics and Topographical Distribution of Surface Glycoproteins during Myoblast Fusion: A Resonance Energy Transfer Study”,Biochemistry,vol. 21, No. 14, pp. 3275-3283, 1982.
Herron, J.N.,Fluorescein Hapten: An Immunological Probe,J.E.W. Voss, Eds., (CRC Press, 1981), pp. 53-55.
Herron et al., “Three-Dimensional Structure of a Fluorescein-Fab Complex Crystallized in 2-Methyl-2, 4-pentanediol”,Proteins: Structure, Function, and Genetics,5:271-280, 1989.
Hlady et al., “Total

Affiliated with

Also associated with

Rating

Assay procedure using fluorogenic tracers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Assay procedure using fluorogenic tracers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay procedure using fluorogenic tracers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3124123